

Osamah Z. Badwan, MDDepartment of Internal Medicine,
Cleveland Clinic, Cleveland, OH**Lorenzo Braghieri, MD**Department of Internal Medicine,
Cleveland Clinic, Cleveland, OH**Warren Skoza, MD**Department of Internal Medicine,
Cleveland Clinic, Cleveland, OH**Ankit Agrawal, MD**Department of Cardiovascular Medicine,
Cleveland Clinic, Cleveland, OH**Venu Menon, MD**Department of Cardiovascular Medicine,
Cleveland Clinic, Cleveland, OH;
Professor, Cleveland Clinic Lerner College
of Medicine of Case Western Reserve
University, Cleveland, OH**W. H. Wilson Tang, MD**Department of Cardiovascular Medicine,
Cleveland Clinic, Cleveland, OH;
Professor, Cleveland Clinic Lerner College
of Medicine of Case Western Reserve
University, Cleveland, OH

Q: When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?

A: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors should be started as early as possible in patients hospitalized with acute decompensated heart failure who do not have clear contraindications to them, and continued after discharge (**Figure 1**). These medications are well tolerated, can aid in decongestion without worsening renal function, and have multiple cardiovascular benefits.

Introduced in 2012, SGLT-2 inhibitors were developed to treat type 2 diabetes by reducing reabsorption of glucose from the renal filtrate, but they have since been found to have multiple cardiovascular benefits beyond glucose-lowering,¹ which may be attributed to their natriuretic and osmotic diuretic effects and other metabolic effects.²⁻⁴ Of note, they lower N-terminal pro-B-type natriuretic peptide levels, which may be a key determinant of improved clinical outcomes regardless of left ventricular ejection fraction.³⁻⁵

■ BENEFITS OF STARTING EARLY

Acute decompensated heart failure is one of the leading reasons for hospital admissions worldwide and is associated with considerable morbidity and mortality.⁶ As outlined below and in **Table 1**,^{3,4,7-11} studies have suggested that patients hospitalized for acute decompensated heart failure could tolerate SGLT-2 inhibitors and derive cardiac benefit from them, especially when these drugs were started early. While most of the patients in these trials had reduced left ventricular ejection fraction, the benefits were consistent across all left-ventricular-ejection-fraction groups.

The **EMPA-RESPONSE-AHF trial** (Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure),⁷ with 79 patients, found patients who were randomized to empagliflozin within 24 hours of admission had a significant reduction in the composite outcome of worsening heart failure, rehospitalization for heart failure, or death at 60 days compared with placebo.

The **EMPULSE trial** (Empagliflozin in Patients Hospitalized With Acute Heart Failure Who Have Been Stabilized)³ found that patients who were randomized to receive empagliflozin 10 mg daily within 5 days of admission had a significant reduction in the combined primary end point, ie, a hierarchical composite of death from any cause, number of heart failure events, and time to first heart failure event, or a 5-point or greater difference in change from baseline in the Kansas City Cardiomyopathy Questionnaire Total Symptom Score at 90 days compared with placebo.

The **DELIVER trial** (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure),¹² in a prespecified analysis of 654 (10.4%) of the trial patients who were randomized to receive dapagliflozin or placebo while hospitalized for heart failure or within 30 days of hospital discharge, demonstrated a reduced risk of worsening heart failure or cardiovascular death. The investigators calculated that the number needed to treat with dapagliflozin to prevent 1 primary outcome event was 28 patient-years in recently hospitalized patients and 65 patient-years in patients not recently hospitalized.

The **SOLOIST-WHF trial** (Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes

doi:10.3949/ccjm.91a.23034




Figure 1. Proposed algorithm for initiating sodium-glucose cotransporter 2 inhibitors in acute decompensated heart failure.

^aDapagliflozin: No dosage adjustment for eGFR ≥ 25 mL/min/1.73 m². Manufacturer labeling does not recommend initiation of therapy at eGFR < 25 mL/min/1.73 m². Sotagliflozin is not indicated for patients with eGFR < 25 mL/min/1.73 m². For heart failure, empagliflozin is not indicated for eGFR < 20 mL/min/1.73 m². For type 2 diabetes mellitus, empagliflozin is not indicated for eGFR < 30 mL/min/1.73 m².

^bDirect evidence on the effects of canagliflozin and ertugliflozin on heart failure outcomes is available only in patients with type 2 diabetes mellitus. It remains to be determined if they have similar effects in patients without type 2 diabetes.

eGFR = estimated glomerular filtration rate; NT-proBNP = N-terminal pro-B-type natriuretic peptide; SBP = systolic blood pressure; SGLT-2 = sodium-glucose cotransporter 2

TABLE 1

Randomized controlled trials of sodium-glucose cotransporter 2 inhibitors in acute decompensated heart failure

Trial	Patients	Treatment	Results
EMPULSE ³	N = 530, 67% with left ventricular ejection fraction (LVEF) < 40%	Empagliflozin 10 mg/day or placebo for 90 days, started a median of 3 days after hospital admission	Early benefit, defined by a hierarchical composite that incorporated all-cause mortality, time to heart failure events, and quality of life (measured by Kansas City Cardiomyopathy Questionnaire Total Symptom Score) with empagliflozin use
EMPAG-HF ⁴	N = 59, mean LVEF 45 ± 16%	Empagliflozin 25 mg/day or placebo for 5 days, started within 12 hours of admission	A 25% increase in cumulative urine output over 5 days without affecting markers of renal function with empagliflozin use
SOLOIST-WHF ^{8,9}	N = 1,222, 79% with LVEF < 50%	Sotagliflozin 200–400 mg/day or placebo for a median of 9 months, initiated before or shortly after hospital discharge	A 33% reduction of a composite of cardiovascular death and hospitalizations or urgent visits for heart failure and apparent improvement in quality of life as measured by the Kansas City Cardiomyopathy Questionnaire 12 score at 4 months in sotagliflozin group
EMPA-RESPONSE-AHF ⁷	N = 79, 100% with LVEF < 50%	Empagliflozin 10 mg/day or placebo for 30 days, initiated within 24 hours of presentation while on intravenous diuretics	Significantly reduced composite outcome of worsening heart failure, rehospitalization for heart failure, or death at 60 days in empagliflozin group
DAPA-RESIST ¹⁰	N = 61, 44% with LVEF ≤ 40%	Dapagliflozin 10 mg or metolazone 5–10 mg for up to 3 consecutive days, initiated within 24 hours of trial screening	Significant weight reductions at up to 96 hours of dapagliflozin use compared with metolazone group
DICTATE-AHF ¹¹	N = 240, 52% with LVEF < 40%	Dapagliflozin 10 mg/day + protocolized diuretic titration or protocolized diuretic titration alone, initiated within 24 hours of presentation	Strong signal of improved diuretic efficiency (defined as weight change divided by loop diuretic dose) until day 5 of hospitalization or discharge if sooner

DAPA-RESIST = Dapagliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic Resistance, DICTATE-AHF = Efficacy and Safety of Dapagliflozin in Acute Heart Failure, EMPAG-HF = Empagliflozin in Acute Decompensated Heart Failure, EMPA-RESPONSE-AHF = Effects of Empagliflozin on Clinical Outcomes in Patients With Acute Decompensated Heart Failure, EMPULSE = Empagliflozin in Patients Hospitalized With Acute Heart Failure Who Have Been Stabilized, SOLOIST-WHF = Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure

Post Worsening Heart Failure),⁸ in a prespecified analysis based on timing of the first dose of the SGLT-1/2 inhibitor sotagliflozin, found the degree of benefit in the primary end point (the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure) was similar regardless of whether the drug was started during the admission (48.8% of the overall group) or within 3 days after discharge. Similarly, a post hoc analysis of this trial demonstrated that starting sotagliflozin before discharge in patients with type 2 diabetes hospitalized for acute decompensated heart failure significantly decreased cardiovascular deaths and heart

failure events through 30 and 90 days after discharge.⁹ However, no trials to date have directly compared SGLT-2 inhibitors with combined SGLT-1/2 inhibitors.

Another advantage of starting these medications while the patient is in the hospital is the opportunity to address medication reconciliation and potential barriers to adherence, which we usually do on discharge.

■ SGLT-2 INHIBITORS HELP REMOVE FLUID

Congestion is thought to be the primary reason patients are hospitalized with acute decompensated heart failure.¹³ Excreting more sodium early during decongestive

therapy is strongly associated with better postdischarge outcomes, and sodium excretion is a better prognostic indicator than urine output, net fluid balance, or weight change.¹⁴

A concern about starting SGLT-2 inhibitors as an add-on therapy (in addition to loop diuretics) is the potential for excessively rapid intravascular volume removal and renal injury. Nevertheless, empagliflozin was shown to achieve decongestion without worsening renal function in patients with type 2 diabetes hospitalized for acute decompensated heart failure.¹⁵ This might be explained by the natriuresis and osmotic diuresis caused by SGLT-2 inhibition, leading to reduced plasma volume and, subsequently, reduced preload.² Furthermore, SGLT-2 inhibitors may act synergistically with loop diuretics for decongestion and have other beneficial metabolic effects.¹⁶

The 2023 DAPA-RESIST trial (Dapagliflozin Versus Thiazide Diuretic in Patients With Heart Failure and Diuretic Resistance)¹⁰ showed that dapagliflozin 10 mg daily was as effective as metolazone 5 to 10 mg daily in alleviating congestion in patients with acute decompensated heart failure with resistance to loop diuretics. Although patients in the dapagliflozin group received a higher total amount of furosemide, they encountered fewer biochemical disturbances than those in the metolazone group.

■ PATIENTS ALREADY ON SGLT-2 INHIBITORS

Although SGLT-2 inhibitors lowered blood pressure only slightly by themselves in large heart failure clinical trials, it is important to consider volume status, especially in those receiving other heart failure agents such as angiotensin receptor-neprilysin inhibitors and loop diuretics, which can increase the risk of orthostasis and falling after the patient goes home. Nevertheless, unless patients have a clear contraindication such as severe hypotension (systolic blood pressure < 90 mm Hg), shock, acute kidney injury, estimated glomerular filtration rate (eGFR) less than 20 or 25 mL/min/1.73 m² (depending on the specific agent), or diabetic ketoacidosis (including euglycemic ketoacidosis), those who are already receiving SGLT-2 inhibitors and are admitted with acute decompensated heart failure would benefit from continuing this therapy.^{3,7-9,12}

Of note, evidence of the beneficial effects of canagliflozin and ertugliflozin on heart failure outcomes is available only in patients with type 2 diabetes, and there is even less evidence currently for outcomes with bexagliflozin. It remains to be determined if these drugs have similar effects in patients without type 2 diabetes.

■ PATIENTS WITH RENAL DYSFUNCTION

While SGLT-2 inhibitors have been shown to slow the progression of chronic kidney disease, they generally are not indicated for patients whose eGFR is less than 20 or 25 mL/min/1.73 m² (depending on the particular SGLT-2 inhibitor). A reason for caution in this situation is that SGLT-2 inhibitors cause a temporary drop in eGFR and persistent reductions in plasma volume. However, this initial nadir in eGFR early after starting SGLT-2 inhibitors partially reverses over the subsequent 6 to 8 weeks. Further, continuation is associated with improved renal and cardiovascular outcomes, and new studies suggest that SGLT-2 inhibitors should not be discontinued unless the eGFR decreases by more than 30%.¹⁷

■ DIABETIC KETOACIDOSIS AND INFECTIONS

SGLT-2 inhibitors are not approved for patients with type 1 diabetes, since their use may promote hypoglycemia in patients without sufficient insulin secretagogue activity, a situation also posing a risk for euglycemic diabetic ketoacidosis.¹⁸ Also, prescribers have been cautioned about genital mycotic infections and the rare severe complication of Fournier gangrene in patients at high risk (eg, older men and those with diabetes, alcohol use disorder, obesity, or immunocompromising conditions).

Fortunately, none of the previously mentioned trials found a higher risk of these complications in patients started on SGLT-2 inhibitors during admissions for acute decompensated heart failure.

■ THE BOTTOM LINE

In patients with acute decompensated heart failure without clear contraindications to these agents, an SGLT-2 inhibitor should be started as early as possible or continued if the patient is already receiving one. As an adjuvant therapy for decongestion, they have been shown to be well tolerated and can aid in decongestion without worsening renal function. Their use early during hospitalization and their continuation after discharge may translate into long-term clinical benefits. ■

■ DISCLOSURES

Dr. Tang has disclosed consulting for Boston Scientific, CardiaTec Biosciences, Cardiol Therapeutics, Genomics, Intellia Therapeutics, Kiniksa Pharmaceuticals, preCARDIA, Relypsa, Renovacor, Sequana Medical, WhiteSwell, and Zehna Therapeutics; board examination writing/approval committee for American Board of Internal Medicine; and editorship/authorship for SpringerNature. The other authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

REFERENCES

1. Bailey CJ, Day C, Bellary S. Renal protection with SGLT2 Inhibitors: effects in acute and chronic kidney disease. *Curr Diab Rep* 2022; 22(1):39–52. doi:10.1007/s11892-021-01442-z
2. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. *Circulation* 2017; 136(17):1643–1658. doi:10.1161/CIRCULATIONAHA.117.030012
3. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. *Nat Med* 2022; 28(3):568–574. doi:10.1038/s41591-021-01659-1
4. Schulze PC, Bogoviku J, Westphal J, et al. Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). *Circulation* 2022; 146(4):289–298. doi:10.1161/CIRCULATIONAHA.122.059038
5. Grodin JL, Tang WHW, Hardin EA. Natriuretic peptides: do they inform the potential for treatment response in HFpEF?. *JACC Heart Fail* 2022; 10(12):914–917. doi:10.1016/j.jchf.2022.10.001
6. Ambrosy AP, Fonarow GC, Butler J, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. *J Am Coll Cardiol* 2014; 63(12):1123–1133. doi:10.1016/j.jacc.2013.11.053
7. Damman K, Beusekamp JC, Boersma EM, et al. Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF). *Eur J Heart Fail* 2020; 22(4):713–722. doi:10.1002/ehfj.1713
8. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. *N Engl J Med* 2021; 384(2):117–128. doi:10.1056/NEJMoa2030183
9. Pitt B, Bhatt DL, Szarek M, et al. Effect of sotagliflozin on early mortality and heart failure-related events: a post hoc analysis of SOLOIST-WHF [published correction appears in *JACC Heart Fail* 2023; 11(9):1288]. *JACC Heart Fail* 2023; 11(8 Pt 1):879–889. doi:10.1016/j.jchf.2023.05.026
10. Yeoh SE, Osmanska J, Petrie MC, et al. Dapagliflozin vs metolazone in heart failure resistant to loop diuretics. *Eur Heart J* 2023; 44(31):2966–2977. doi:10.1093/eurheartj/ehad341
11. Cox ZL, Collins SP, Aaron M, et al. Efficacy and safety of dapagliflozin in acute heart failure: rationale and design of the DICTATE-AHF Trial. *Am Heart J* 2021; 232:116–124. doi:10.1016/j.ahj.2020.10.071
12. Cunningham JW, Vaduganathan M, Claggett BL, et al. Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction. *J Am Coll Cardiol* 2022; 80(14):1302–1310. doi:10.1016/j.jacc.2022.07.021
13. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). *Am Heart J* 2005; 149(2):209–216. doi:10.1016/j.ahj.2004.08.005
14. Hodson DZ, Griffin M, Mahoney D, et al. Natriuretic response is highly variable and associated with 6-month survival: insights from the ROSE-AHF Trial. *JACC Heart Fail* 2019; 7(5):383–391. doi:10.1016/j.jchf.2019.01.007
15. Tamaki S, Yamada T, Watanabe T, et al. Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: a prospective randomized controlled study [published correction appears in *Circ Heart Fail* 2021; 14(4):e000067]. *Circ Heart Fail* 2021; 14(3):e007048. doi:10.1161/CIRCHEARTFAILURE.120.007048
16. Griffin M, Rao VS, Ivey-Miranda J, et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. *Circulation* 2020; 142(11):1028–1039. doi:10.1161/CIRCULATIONAHA.120.045691
17. Adamson C, Docherty KF, Heerspink HJL, et al. Initial decline (dip) in estimated glomerular filtration rate after initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. *Circulation* 2022; 146(6):438–449. doi:10.1161/CIRCULATIONAHA.121.058910
18. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. *Diabetes Care* 2015; 38(9):1687–1693. doi:10.2337/dc15-0843

Address: W. H. Wilson Tang, MD, Department of Cardiovascular Medicine, J3-4, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; tangw@ccf.org

When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?

In the January 2024 issue, the article by Badwan OZ, Braghieri L, Skoza W, Agrawal A, Menon V, Tang WHW. *When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?* *Cleve Clin J Med* 2024; 91(1):47–51. doi:10.3949/ccjm.91a.23034 contained an error in **Figure 1**. The dosage of empagliflozin was given as 10–25 mg twice daily. The correct dosage is 10–25 mg once daily. The corrected version appears below:




Figure 1. Proposed algorithm for initiating sodium-glucose cotransporter 2 inhibitors in acute decompensated heart failure.

^aDapagliflozin: No dosage adjustment for $\text{eGFR} \geq 25 \text{ mL/min/1.73 m}^2$. Manufacturer labeling does not recommend initiation of therapy at $\text{eGFR} < 25 \text{ mL/min/1.73 m}^2$. Sotagliflozin is not indicated for patients with $\text{eGFR} < 25 \text{ mL/min/1.73 m}^2$. For heart failure, empagliflozin is not indicated for $\text{eGFR} < 20 \text{ mL/min/1.73 m}^2$. For type 2 diabetes mellitus, empagliflozin is not indicated for $\text{eGFR} < 30 \text{ mL/min/1.73 m}^2$.

^bDirect evidence on the effects of canagliflozin and ertugliflozin on heart failure outcomes is available only in patients with type 2 diabetes mellitus. It remains to be determined if they have similar effects in patients without type 2 diabetes.

eGFR = estimated glomerular filtration rate; NT-proBNP = N-terminal pro-B-type natriuretic peptide; SBP = systolic blood pressure; SGLT-2 = sodium-glucose cotransporter 2